Rudolf Krska Receives B.R.A.I.N Award
Rudolf Krska of the University of Natural Resources and Life Sciences (BOKU), in Vienna, Austria, has been awarded the biennial B.R.A.I.N award at the Biomin scientific conference held in Vancouver, Canada.
Rudolf Krska of the University of Natural Resources and Life Sciences (BOKU), in Vienna, Austria, has been awarded the biennial B.R.A.I.N award at the Biomin scientific conference held in Vancouver, Canada.
As of 2013, Krska is the most-cited author on the topic of mycotoxins in the past decade, and this enormous contribution was highlighted as a key reason for Krska winning the award by the selection committee.
“Dr. Krska is a high flier in the field of mycotoxins who is well-recognized for his expertise by his peers,” said Eva Maria Binder, Chief Research Officer at the Erber Group.
Further to Krska’s ongoing work as a research scientist, his 20+ year track record of working with the Biomin Research Centre, part of the Erber Group, on numerous projects also contributed to him receiving the honour.
Biomin Founder and President of the Supervisory Board of Erber Group, Erich Erber, remarked that Rudolf Krska “is one of the most outstanding scientists I have come across in
my life. When we met [for the] first time in 1994 to discuss a common project on mycotoxins we could not imagine
where we stand today.”
Krska received his award on the final day of the scientific conference at the 2016 World Nutrition Forum, which included the B.R.A.I.N trophy and a check for $10,000.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
